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Highlights (85 per point): 
• Alemtuzumab dosing in unrelated reduced intensity transplantation is 
undefined. 
 
• 60mg Alemtuzumab provides equivalent control of GVHD compared with 
100mg 
 
• 50mg Alemtuzumab is associated with threefold increased risk of severe 
acute GVHD. 
 
Short title 
Alemtuzumab scheduling in unrelated donor allografts 
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Abstract  
Alemtuzumab conditioning is highly effective at reducing the incidence of acute and 
chronic graft versus host disease (GVHD) in reduced intensity fludarabine and 
melphalan transplantation with ciclosporin monotherapy.  Less frequent and lower 
dose scheduling may be used with sibling donors but an optimal regimen for 
matched unrelated donors has not been defined.  In this retrospective observational 
study of 313 patients, the incidence and severity of GVHD was compared in patients 
receiving the standard 100mg regimen (20mg on day -7 to -3), 60mg (30mg day -4 
and -2) or 50mg (10mg on day -7 to -3).  Patients treated with 100mg, 60mg or 50mg 
developed acute GVHD grade I-IV with an incidence of 74%, 65% and 64%, 
respectively, while 36%, 32% and 41% developed chronic GHVD.  An excess of 
severe acute grade III/IV GVHD was observed in the 50mg cohort (15% vs. 2-6%;  p 
= 0.016).  The relative risk of severe acute grade GVHD remained more than three-
fold higher in the 50mg cohort, compared with 100mg, after adjustment for 
differences in age, gender mismatch, CMV risk and diagnosis (p = 0.030).  The 
findings indicate that 60mg  doses of alemtuzumab is comparable to 100mg but 
lower dosing may increase the risk of severe grade GVHD. 
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Introduction 
Alemtuzumab (humanized anti-CD52 antibody) is highly effective at reducing the 
incidence of acute and chronic GVHD in the setting of reduced intensity 
transplantation with fludarabine and melphalan (1-7).  When delivered to recipients 
during conditioning therapy, it effects in vivo depletion of both recipient and donor T 
cells, NK cells, B cells, monocytes and dendritic cells, owing persistence in the 
recipient with a half life of 8 days (8-11).  Freedom from GVHD is associated with 
partial chimerism of donor T cells but this may be corrected with donor lymphocyte 
infusions to deliver good overall survival with minimal long term morbidity (7,12-14). 
 
The original fludarabine, melphalan and alemtuzumab regimen used an empiric 
alemtuzumab dose of 100mg comprising five 20mg doses given on consecutive days 
between day -7 and -3.  This regimen is effective at abrogating GVHD in mixed 
cohorts of matched related and unrelated donor transplants used to treat patients 
with both myeloid and lymphoid malignancy  (1-7).  It has also been noted that 
GVHD is well controlled in PBSC and BM grafts from unrelated donors (15) and that 
a degree of antigen mismatching is well tolerated (16).  Similar doses of 
alemtuzumab have also been used with other fludarabine-based reduced intensity 
protocols with equivalent efficacy (14).   
 
Excessive T cell depletion may be associated with increased relapse and risk of 
infection (11,17-19) and several groups have shown that dose reduction is possible 
in unrelated donor transplantation.  A number of schedules with doses of between 
50-100mg, administered over 2-5 days, have been tested (20-22) and it is reported 
that as little as 10mg reduces the burden of GVHD (23). A phased dose de-
escalation study in sibling transplants concluded that a single dose of 30mg on day -
1 was sufficient to reduce GVHD to a similar level as 100mg of alemtuzumab (24) 
but a comparable study has not been performed using only unrelated donors in a 
common protocol.    Retrospective comparison of 30mg and 60mg dosing in sibling 
and unrelated donor transplants, respectively, indicated that the unrelated cohort still 
experienced more GVHD and had higher donor T cell chimerism (25).   
 
Owing to the long in vivo half-life of alemtuzumab, the total dose and scheduling both 
have the potential to modify GVHD risk substantially (11) but there is no consensus 
about an optimal regimen in fludarabine-melphalan unrelated donor transplantation.  
Here we report a retrospective observational study in which we compared three 
commonly used protocols.   Reduction and compression of the alemtuzumab 
schedule to two 30mg doses on day -4 and -2 was comparable to 100mg between 
days -7 to -3 but patients receiving 50mg alemtuzumab between day -7 to -3 were at 
greater risk of severe acute grade III/IV GVHD. 
 
Methods 
Patients and donors 
Data were collated from three UK transplant centers: University College 
Hospital/Royal Free Hospital, University College London Hospitals NHS Foundation 
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Trust, London; Northern Centre for Bone Marrow Transplantation, Newcastle upon 
Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne; and, Queen Elizabeth 
Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham.  
Sequential patients transplanted between January 2007 and December 2011 were 
included. Patients were over the age of 18 years at transplantation, had a 
hematological malignancy at any stage and were transplanted with an unrelated 
donor with at least 8/10 HLA four digit allele matching.  The number of transplants 
with less than 10/10 matching was too small to discern differences between A, B, C, 
or DQ antigen mismatches.  The major stem cell source was PBSC at all centers.  
All patients gave consent for their clinical data to be reported anonymously according 
to local ethical approval.  Clinical data were collected by transplant center data 
managers and analyzed by KG, KP and MC. 
 
Conditioning and alemtuzumab dosing 
All patients were conditioned with five doses of fludarabine 30mg/m2 daily days -7 to 
-3 and melphalan 140mg/m2 day -2.  GVHD prophylaxis consisted of ciclosporin 
monotherapy starting at 3mg/kg/day adjusting to an initial level of at least 200ng/ml.  
Each center delivered a different alemtuzumab schedule.  London patients received 
100mg in five 20mg daily doses given consecutively from day -7 to day -3  
Newcastle patients received 60mg as two 30mg doses on day -4 and day -2 and 
Birmingham patients received 50mg in five 10mg doses given consecutively from 
day -7 to day -3.  Donor lymphocyte infusions (DLI) were given for mixed chimerism 
in all centers according to three monthly escalating schedules starting at 6 months 
post transplantation with a dose of 1 x 106 CD3+ cells per kg. 
Study endpoints 
The primary endpoints of the study were the raw incidence and severity of acute 
GVHD and the cumulative incidence of chronic GVHD.  Secondary endpoints 
included donor T cell chimerism, CMV reactivation, non-relapse mortality (NRM), 
relapse and overall survival.  Patients were evaluable for acute GVHD if they 
survived until engraftment  and for chronic GVHD if they lived more than 100 days.  
CMV reactivation was defined as more than 2 sequential blood PCR results > 2 x103 
copies/ml or requiring anti-CMV therapy with ganciclovir, valganciclovir or foscarnet. 
Statistical analysis 
Analysis was performed according to EBMT guidelines (26-29), on consecutive 
patients transplanted between January 2007 and December 2011. Chi-square, 
Mann-Witney tests and Kaplan-Meier survival curves were plotted with GraphPad 
Prism 6 and cumulative incidence analysis with competing risks was performed with 
the cmprsk.  function of the open-source software R.  Kaplan-Meier curves were 
compared with log-rank (Mantel-Cox) tests while cumulative incidence curves were 
compared with Gray’s test .  Patients were censored at last follow up and at the time 
of receiving DLI for the analysis of chronic GVHD.  Multivariate analysis was 
performed in SPSS using binary logistic regression (grade II/IV vs other)  
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Results 
In this three-center retrospective observational study, we compared the incidence 
and severity of acute GVHD in patients receiving fludarabine 150mg/m2 and 
melphalan 140mg/m2 combined with the original 100mg alemtuzumab regimen 
(n=134) (1),  or one of two alternative schedules: 60mg given as two doses of 30mg, 
day -4 and day -2 (n=72) (25); or 50mg administered as five doses of 10mg, days -7 
to -3 (n=107) (20,21).  Conditioning protocols are summarized in Figure 1. 
 
 
 
Figure 1.  Preparative regimens 
Outline of preparative regimens for the three patient cohorts. 
 
Patient characteristics 
Consecutive patients recruited at each center were included in the study.  Several 
differences were noted in the patient characteristics reflecting local practice and 
referral bias, summarized in Table 1.  Patients in each cohort were matched for 
donor cell source (90-97% receiving PBSC), HLA matching (69-83% at least 10/10), 
disease status and follow up.  There were however significant differences in age, the 
proportion of female to male transplants, the frequency of high risk CMV positive 
recipients and the distribution of disease between acute myeloid leukemia and 
lymphoproliferative disease.  The 50mg cohort had the highest rate of high risk CMV 
serostatus (negative into positive; 25.23%; p = 0.0058) and patients were more likely 
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to have a diagnosis of AML or MDS (62.62%; p = 0.0005).  Patients receiving 60mg 
of alemtuzumab were younger (median age 45;  p = 0.0051) and had no female to 
male transplants (p = 0.009).  Patients receiving 100mg  had the highest rate of 
female to male transplants (21.82%;  p = 0.009)) and the most patients with 
lymphoproliferative disease (48.51%; p = 0.0005).  
 
 50mg (n =107) 
60mg 
(n =72) 
100mg 
(n =134) P-value 
Age at transplantation 
Median (range) 56 (24-71) 45 (22-67) 50 (21-67) 0.0051 
Graft 
Peripheral blood 97.20% 90.28% 97.47% 0.0551 Bone marrow 2.80% 9.72% 2.53% 
HLA status 
10/10 69.16% 83.33% 70.90% 0.1002 <10/10 30.84% 16.67% 29.10% 
Gender (donor/recipient) 
Female to male 5.61% 0.00% 21.82% 0.009 
CMV (donor/recipient) 
      -       / positive 42.99% 38.89% 40.30% 
0.018 positive  / negative 25.23% 12.50% 11.94% 
negative / negative 31.78% 48.61% 47.76% 
Disease indication 
ALL 3.74% 1.39% 3.73% 
0.0005 
AML/MDS 62.62% 50.00% 32.84% 
Lymphoproliferative 
disorders 25.23% 44.44% 48.51% 
Other 8.41% 4.17% 14.93% 
Status at transplantation 
Untreated 5.61% 2.78% 3.73% 
0.0909 
Partial remission 10.28% 6.94% 17.91% 
Complete remission 74.77% 81.94% 55.22% 
Relapse/progression 5.61% 4.17% 6.72% 
Other 3.74% 4.17% 16.42% 
Follow up period 
Median follow up (months) 18.12 21.63 19.12 0.3339 
Table 1.  Patient Characteristics 
Summary of patient demographics, donor source, HLA matching and gender, CMV 
serostatus, disease and disease status at transplantation.  Differences between 
cohorts were compared with t-tests or contingency analysis and p values were 
derived.  Significantly outlying values by 2x2 chi-square tests are indicated in bold in 
the table.  
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Acute GVHD 
There were no differences in the overall incidence of acute GVHD between the three 
cohorts of patients with 64-74% of patients experiencing at least grade I GVHD and 
32-40% of patients experiencing clinically significant grade II-IV GVHD in all cohorts 
(Figure 2A).  However there distribution of acute GVHD grades was skewed (p = 
0.0124 for all grades), with an excess of grade III/IV acute GVHD in the 50mg cohort 
(15% compared with 2-6%; p = 0.0161 for grades III-IV vs. grades 0-II; chi-square 
tests).  The 50mg and 100mg cohorts had a slighter higher percentage of <10/10 
HLA-matched donors than the 60mg cohort but this was not a significant baseline 
difference and <10/10 matched donors did not experience more GVHD, within each 
cohort.  
 
 
Figure 2. Overall incidence of acute GVHD 
A. Comparison of maximal acute GVHD grades between cohorts.  No significant 
difference was detected by chi square tests between cohorts. 
B. Comparison of maximal acute GVHD grade between ≥ 10/10 and <10/10 matched 
unrelated donor transplants within each cohort.  There were no significant 
differences by chi square tests. 
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Although the proportion of <10/10 matched donors not reach significance between 
the cohorts, the relationship between alemtuzumab dose and HLA matching was 
explored by dividing each cohort into 10/10 and <10/10 antigen matched subgroups 
(Figure 2B).  There were no significant differences in any cohort in the rate of GVHD 
between the two subgroups nor was the control of severe grade GVHD in the <10/10 
patients improved by higher dosing of alemtuzumab.  Paradoxically, less severe 
GVHD was observed in the 60mg cohort who received a <10/10 antigen matched 
donor, presumably due to confounding factors in the selection of lower risk patients 
or anticipatory adjustment of post-transplant immunosuppression. 
Multivariate analysis 
Although an apparent excess of grade III/IV acute GVHD was observed in the 50mg 
cohort, several variables that might affect the incidence of GHVD were non-randomly 
distributed between the cohorts.   These included: patient age, frequency of female 
into male and CMV negative into positive transplants and indication for 
transplantation.  A multivariate analysis was therefore performed to analyse the 
variables that might predict the bivariate outcome grade III/IV GVHD vs all other 
grades.  The covariates considered were Alemtuzumab dose 100mg, 60mg or 50mg; 
age group <40, 41-60 and >60; female into male or other; CMV negative into positive 
or other; and, diagnosis MDS/AML or NHL.  In a general linear model, older age, 
female into male, CMV high risk and NHL were associated with increased but non-
significant risk of grade III/IV acute GVHD. Only alemtuzumab dose was significantly 
predictive of grade III/IV GVHD conferring more than a three-fold increased risk, 
which remained after adjustment for the other variables (Table 2). 
 
Variable 
Univariate 
Relative Risk 
of GVHD III/IV 
p  value 
Multivariate 
Relative risk 
of GVHD III/IV  
p value 
Alemtuzumab 60mg vs 
100mg 1.067 0.920 0.852 0.811 
Alemtuzumab 50 mg vs 
100mg 3.190 0.014 3.031 0.030 
Age 41-60 vs <40 0.847 0.783 0.653 0.477 
Age >60 vs <40 0.607 0.285 1.172 0.832 
F into M vs other 2.934 0.300 2.959 0.338 
CMV neg pos vs other 1.491 0.415 1.409 0.510 
NHL vs MDS/AML 1.808 0.376 2.083 0.162 
 
Table 2.  Mulitvariate analysis of the risk of grade III/IV acute GVHD 
Effect of covariables on the incidence of grade III/IV GVHD.  Only Alemtuzumab 
dose has a significant effect which remains after accounting for other variables that 
are non-randomly distributed between the groups and could have influenced GVHD. 
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Chronic GVHD 
The cumulative incidence of chronic GVHD was similar in all cohorts ranging from 
33% in the 100mg and 32% in the 60mg cohort, to 41% in the 50mg cohort at two 
years (p = 0.6248) (Figure 3A).  Although there was a trend for more chronic GVHD 
in the 50mg cohort, the number of patients with extensive chronic GVHD was not 
increased between the cohorts  (p = 0.1612) (Figure 3B).    
 
 
Figure 3. Incidence and severity of chronic GVHD 
A. Comparison of cumulative incidence of chronic GVHD analyzed with relapse and 
death as competing risks.  Patients were censored at last follow up or at the point of 
receiving donor lymphocyte infusion.  No significant difference was detected 
between cohorts. 
B Comparison of the maximal severity of chronic GVHD between cohorts.  No 
significant difference was detected between cohorts.  
 
Engraftment and donor chimerism 
In keeping with previous reports, the rate of engraftment and achievement of 
complete donor myeloid chimerism was more than 95% in all cohorts (not shown).  
The level of donor T cell chimerism was however very variable (Figure 4A).  
Green et al 2016  12/22 
Analysis was constrained by the reporting donor chimerism in the 100mg cohort in 
bands of 0-49; 50-94 and ≥95, so data from the other cohorts were transformed to 
match.  Only just over half of all patients achieved more than 95% donor chimerism 
with the lowest levels of donor T cell chimerism observed in the 60mg cohort (p = 
0.0460).  This may reflect a lower proportion of mismatched donors or more liberal 
use of post-transplant immunosuppression in this cohort.  Continuously distributed 
data were available for the 50mg and 60mg cohorts and showed a significant 
skewing between cohorts with lower median T cell chimerism in the 60mg cohort 
(85% vs. 96%; p = (Figure 4B). 
 
 
 
Figure 4. Chimerism 
A. Donor T cell chimerism at 100 days.  Bins of 0-50; 50-95 and 95-100 were 
selected based on the discontinuous data available for the 100mg cohort.  A 
significant difference was detected owing to lower T cell chimerism in the 60mg 
cohort. 
B. Comparison of donor T cell chimerism at 100 days for patients in 50mg and 60mg 
cohorts showing skewing towards lower median T cell chimerism in the 60mg cohort 
(Mann-Witney test). 
CMV reactivation 
The risk of CMV reactivation is high with alemtuzumab containing regimens.  More 
than 80% of patients in all cohorts with high risk serostatus (positive recipient) had a 
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positive CMV PCR result after transplant.  Intermediate status (positive donor into 
negative recipient) reactivation was similar in all cohorts.  Within the high risk 
serostatus groups, significantly higher rates of reactivation were observed in the 
100mg cohort (p= 0.0267) (Figure 5). 
 
 
Figure 5. CMV reactivation 
The proportion of patients in each cohort requiring treatment for CMV reactivation, 
according to CMV risk status.  A higher risk of reactivation was detected for high risk 
CMV positive recipients in the 100mg cohort (*). 
 
Mortality and survival 
No significant differences were observed in the cumulative incidence of non-relapse 
mortality at 2 years between 100mg, 60mg and 50mg cohorts (16%, 16%, and 24%, 
respectively; p = 0.3232) (Figure 6A) or relapse rates at 2 years (36%, 24%, and 
29%, respectively; p = 0.3454) (Figure 6B).  The overall survival of each cohort was 
not significantly different and is shown for the major disease groups AML/MDS and 
NHL (Figure 6C).  There were no differences within each cohort when 10/10 or 
<10/10 matched donors were compared or when disease subgroups were analyzed 
(not shown).   
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Figure 6.  Outcome 
B.  Cumulative incidence of NRM with relapse as a competing factor showing no 
significant difference between the cohorts by Gray’s test. 
A.  Cumulative incidence of relapse with NRM as a competing factor showing no 
significant difference between the cohorts by Gray’s test. 
C. Overall survival for patients with i) AML/MDS or ii) NHL by cohort. Kaplan-Meier 
curves were compare by Log Rank (Mantel-Cox) test. 
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Discussion 
The use of T cell depletion remains controversial in all forms of allogeneic bone 
marrow transplantation but particularly in the setting of reduced intensity 
conditioning, where it is argued that graft versus tumor effects need to be stronger to 
compensate for attenuated cytoreduction(19,30).  However, even with minimal 
conditioning,  T replete transplants still incur a similar burden of graft versus host 
disease to full intensity transplants albeit with delayed kinetics(31).  The prevalence 
of GVHD with reduced intensity conditioning is further amplified by the increasing 
age of eligible patients and widespread use of peripheral blood stem cells.  For these 
reasons, many UK centers have developed reduced intensity protocols using 
alemtuzumab to effect in vivo T cell depletion and reduce acute GVHD(1-7).  This 
approach is supported by a retrospective comparison of T depletion strategies with 
reduced intensity regimens showing superior control of acute and chronic GVHD and 
a trend for greater overall survival with alemtuzumab-containing regimens, despite 
higher relapse rates (19).  These data underscore the need to define optimal dosing 
regimens that balance the risks of toxicity and relapse. 
 
Several cohort studies have compared protocols with and without alemtuzumab and 
arrived at the conclusion that overall survival is similar and survivorship quality is 
enhanced even though there are higher rates of relapse and CMV reactivation in 
patients given alemtuzumab.  In sibling transplants for lymphoproliferative disease, 
acute and chronic GVHD was reduced by alemtuzumab with no impact on overall 
survival (32).  In a comparison of patients with AML, alemtuzumab reduced the 
incidence of extensive chronic GVHD from 47% to 4% and was associated with 
slightly superior survival than those not receiving alemtuzumab (5).  This study 
included sibling and matched unrelated donor transplants given a range of 
alemtuzumab doses from 30mg to 100mg.  Another more controlled study of sibling 
and unrelated transplants for AML showed that 100mg alemtuzumab reduced the 
incidence of acute grade II-IV GVHD from 58.1% to 23.3% and chronic GVHD from 
78.4% to 16.0%  with no difference in overall survival(33).  Increases in the rate of 
CMV reactivation with alemtuzumab do not appear to impact on survival with modern 
pre-emptive antiviral therapy (34).  Although intervention with DLI may be required to 
achieve an optimal outcome in alemtuzumab-containing transplants, recipients of 
DLI appear to enjoy a favorable outcome in both lymphoid and myeloid malignancy 
(14,35). 
 
These results indicate that fludarabine-melphalan reduced intensity transplantation is 
feasible with or without alemtuzumab but the question remains whether it is possible 
to define an optimal dose of alemtuzumab that achieves good control of GVHD and 
survivorship without excessive detriment to immune reconstitution.  A phase II study 
in sibling transplants reported that a significant dose reduction to a single 30mg vial 
at day -1 almost completely ablated acute grade II-IV GVHD and extensive chronic 
GVHD (both 4%).  Another dose reduction study using a variety of fludarabine-based 
regimens showed that lower doses were also feasible in mixed sibling and unrelated 
donors given a variety of conditioning regimens, but there was insufficient power to 
discriminate between different dose levels (23)  
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In unrelated donor transplants, there does not appear to be a simple linear 
relationship between alemtuzumab dose and GVHD risk.  At the highest 
alemtuzumab dose of 100mg, the rate of grade II-IV GVHD in our study was 
approximately 10-fold higher (40%) than sibling transplants exposed to 30mg of 
alemtuzumab (4%), although the majority was grade II, and remained relatively 
constant with 60mg and 50mg dosing.  This is consistent with a previous report of 
unrelated donors transplants performed with 100mg of alemtuzumab(16).  A recent 
study comparing the 60mg schedule for unrelated donors with 30mg for sibling 
transplants showed similarly high rates of grade II-IV GVHD (44%) and donor T cell 
chimerism in the unrelated transplants(25).  Reducing alemtuzumab to 40mg or less 
did not appear to increase the rate of grade II-IV acute GVHD in a series of small 
cohorts (23).  However, below 60mg, there may be a trend towards increasing 
severe grade III/IV acute GVHD.   In our study, patients receiving 50mg experienced 
15% grade III/IV acute GVHD compared with 2-6% in the 60mg and 100mg cohorts.  
This bias was also observed in the 10/10 matched donors.  An even higher rate of 
23.8% severe acute grade III/IV GVHD was reported in unrelated donor transplants 
receiving 40mg of alemtuzumab although this did not further increase when 
alemtuzumab dose was reduced to 20mg and 10mg (23). 
 
The scheduling of alemtuzumab has a significant impact on plasma concentration on 
the day of transplant(11).  We have previously demonstrated that the 60mg regimen 
results in a similar level of alemtuzumab to the 100mg regimen at 5-6µg/ml on day 
+1 (25), thus it is not surprising that comparable control of GVHD was observed.  It 
would be erroneous to conclude that 60mg was a safe threshold dose without 
reference to the timing of administration.  The excess of severe acute GVHD in the 
50mg cohort probably reflects earlier scheduling as much as a lower total dose, 
resulting in a substantially lower in vivo concentration.  Although Alemtuzumab levels 
have not been measured in this regimen, the continuously distributed T cell 
chimerism at day 100 is consistent with a much lower level of donor T cell depletion 
in the 50mg cohort, compared with the 60mg cohort.  Even later scheduling of two 
30mg doses to day -2 to -1 has been proposed and is likely to deliver alemtuzumab 
concentrations that exceed the original 100mg regimen(36).  The 100mg dose of 
alemtuzumab may be used with <10/10 antigen matched donors(16) and it appeared 
here that reduction to 60mg or 50mg did not significantly increase GVHD, relative to 
patients with 10/10 matched donors given the same prophylaxis. 
 
 
The main limitation of this study is the difficulty in controlling center bias.  The 
increase in grade III/IV acute GVHD in the 50mg cohort remained after adjustment 
for the major covariables that might have influenced GVHD, but other factors such as 
performance status and disease status could not be completely controlled for.  Other 
less tangible bias may have been introduced by variations in clinical practice such as 
the use of post-transplant immunosuppression.  Although centers reported similar 
operating procedures governing the withdrawal of ciclosporin, ciclosporin levels were 
not collected as primary data.  Donor lymphocyte infusion data were not studied 
because the intention was to analyze acute and chronic GVHD arising directly from 
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the allograft procedure.  All centers reported using a similar escalating regimen and 
administration of DLI was a censoring event.   
 
In conclusion, this study suggests that it is feasible to use two 30mg doses of 
alemtuzumab in fludarabine-melphalan unrelated donor transplants without 
significantly increasing the risk of GVHD or impairing outcome compared with the 
original 100mg dose.  Given at day -4 and -2, this results in similar plasma levels 
compared with five 20mg doses (25) and is cheaper, assuming a 30mg vial size.  
Further dose reduction may be feasible with later scheduling (day -2 to -1) and 
ideally, should be studied prospectively with in vivo alemtuzumab levels and 
accurate T cell chimerism, in addition to clinical outcome data.  The current 50mg 
regimen in use in the UK was associated with an increased risk of severe grade III/IV 
acute GVHD, although confounding factors may have increased the baseline risk in 
this cohort.  Overall, the use of T cell depletion remains subject to historical 
precedent and individual center bias regarding the acceptable burden of GVHD in 
transplant survivors.   
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